Nektar Expects Its $952.9 Million Cash Pile To Last Beyond Initial Trial Results

Research spending rose as the company advanced its lead drug, with initial late-stage dermatitis results expected in summer 2028.

Share
Nektar Expects Its $952.9 Million Cash Pile To Last Beyond Initial Trial Results

Nektar Therapeutics, which develops experimental immune-system medicines for autoimmune diseases and cancer, reiterated Thursday that its $952.9 million in cash and marketable securities should fund operations beyond initial late-stage dermatitis trial results. The projection, restated in Friday's SEC filing, keeps its funding outlook intact as research spending climbs.

Funding Through The Dermatitis Readout

Nektar expects the balance, measured at September 30, to support operations into the third quarter of 2028, consistent with its earlier guidance. It expects the first results from its late-stage atopic dermatitis studies in summer 2028.

That timetable puts the initial results inside the period management expects its existing funds to cover. Both the funding horizon and the results schedule remain company projections.

All three global late-stage atopic dermatitis trials of rezpegaldesleukin have begun, Nektar confirmed in Thursday's results announcement. Rezpegaldesleukin is its lead candidate.

Trial Work Raises Research Costs

Third-quarter research and development spending rose to $44.1 million from $27.3 million a year earlier. Nektar attributed the increase mainly to late-stage trials and manufacturing work for rezpegaldesleukin.

The third-quarter net loss widened to $55.7 million from $35.5 million a year earlier. The higher research bill sits alongside an unchanged estimate of how long the company's funds will last.

An Immune-Drug Pipeline And Licensing Business

Nektar develops treatments for autoimmune and inflammatory diseases. Rezpegaldesleukin is a self-administered injection being studied for atopic dermatitis and alopecia areata. Another candidate, NKTR-255, is designed to stimulate immune responses against cancer.

The company also licenses drug technologies to biotechnology and pharmaceutical businesses under agreements that may produce milestone payments and royalties from commercial sales. More than ten products using its PEGylation technology—which attaches a polymer to a drug—have received regulatory approval in the U.S. or Europe.

Nektar expects its late-stage alopecia areata trial to begin in December, earlier than previously planned. That would extend rezpegaldesleukin's late-stage development work beyond the dermatitis program.

Nektar is targeting its first FDA approval application in 2029; its current funding projection extends into the third quarter of 2028.

Sources

More on Nektar Therapeutics

All Nektar Therapeutics (NKTR) coverage →